Acute Coronary SyndromePhase 2NCT00614354
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
A Phase 2 study testing 99mTc-glucarate solution in people with Acute Coronary Syndrome, run by Molecular Targeting Technologies, Inc. at 4 sites in United States.
Trial summary
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Coronary Syndrome
- What is being tested?
- 99mTc-glucarate solution
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 4 sitesUnited States
- Study dates
- Oct 2008to Sep 2010
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Chest pain of recent onset (less than 24 hours) and of greater than 5-minute duration, consistent with ACS;
- History of CAD;
- Creatinine level less than 3.5 mg per deciliter;
- Female patients who are: surgically sterile (hysterectomy or bilateral tubule libation), at least one year post-menopausal, or have a negative pregnancy test on the day of treatment; and
- Written informed consent.
- This research is being supported by the NIH/NHLBI which requires a minimum 50% participation from women. Efforts should be made to enroll equal numbers of men and women at each clinical site.
Who cannot join
- ECG changes diagnostic of AMI;
- A cardiac revascularization procedure within the last 2 weeks (non-revascularization procedures such as cardiac catheterization, stress test or echocardiography are acceptable);
- An alternate diagnosis more probable than ACS;
- Presence of pericarditis, myocarditis, acute aortic dissection, pneumothorax, or pulmonary embolism (PE);
- Patients with uncontrolled severe heart failure at the time of enrollment (NYHA class III and IV).
- Other serious or life-threatening disease that might preclude a subject from completing this study;
Show all 9Show fewer
- Clinically essential procedures with which this protocol may interfere;
- Previous 99mTc-based diagnostic test within the last 24 hours;
- Female subjects who are pregnant or lactating;
Trial locations and contacts
4 sites in 1 country.
United States4 sites
University of Alabama at Birmingham
Birmingham, Alabama, 35294
University Hospital Case Medical Center
Cleveland, Ohio, 44106
Yale University
New Haven, Connecticut, 06520
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
About this study
Official title: Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.
Read the detailed description
Acute coronary syndrome encompasses a range of coronary artery diseases, including unstable angina and both ST-segment elevation and non-ST-segment elevation myocardial infarction (MI). Differentiating ACS from noncardiac chest pain remains a challenge in the emergency department (ED). Myocardial perfusion imaging (MPI) for ischemia has been used to rule ACS in or out among chest pain patients with nondiagnostic ECGs upon presentation to the ED. Several studies have shown a high negative predictive value of MPI for ruling out acute ischemia in the emergency setting. Although myocardial imaging with perfusion agents provides important information for risk-stratifying stable post-ACS patients, this method is of limited value in patients with prior history of CAD, since these patients will often have abnormal resting perfusion patterns, thereby precluding the ability to differentiate old infarcts from new ischemic events. 99mTc-glucarate does not detect old MIs and thus should provide an improvement in specificity in the imaging of ACS patients with previous CAD.
This study proposes to extend the evaluation of 99mTc-glucarate imaging by studying its ability to detect ACS in chest pain patients with no obvious signs of AMI but with known CAD, in the setting of the ED. Unlike MPI, 99mTc-glucarate imaging will not detect old MIs, thereby providing an advantage in specificity of the technique.
- Conditions
- Acute Coronary Syndrome
- Being tested
- 99mTc-glucarate solution
- Keywords
- 99mTc-glucarate imaging to detect acute coronary syndrome
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
99mTc-glucarate solutionDrug
Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: 99mTc-glucarate solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Readers will assess images as either positive or negative and note the location of uptake.
Measured: Immediately and end of enrolement
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2008 (estimated)
- Study startOct 2008
- Primary completionSep 2010
- Study completionSep 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Molecular Targeting Technologies, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), Yale University, University of Pittsburgh, University of Alabama at Birmingham, University Hospitals Cleveland Medical Center
- Responsible party
- Sponsor
- Investigators
- Albert J. Sinusas, MD, Principal investigator, Yale UniversityDiwakar Jain, MD, Study chair, Drexel UniversityPrem Soman, MD, Ph.D., Principal investigator, University of PittsburghAmi E Iskandrian, MD, Principal investigator, University of Alabama at BirminghamRobert S Jones, MD, Principal investigator, University Hospitals Cleveland Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00614354
- Sponsor's protocol ID
- MTTI ACS 201
- Other IDs
- 5R44HL062770-06
- Status last verified
- Oct 2012
- First submitted
- 30 Jan 2008
- Last updated
- 24 Oct 2013
- Results posted
- No
- Data monitoring committee
- No